Hilma Biocare Introduces new products – Tirzepatide and Retatrutide.

Hilma Biocare introduces new products – Tirzepatide and Retatrutide. These innovative medications are designed to treat type 2 diabetes and promote weight loss in obesity. Tirzepatide is a dual-action drug: a GLP-1 and GIP receptor agonist. Retatrutide is a triple agonist of the GLP-1, GIP, and glucagon receptors. These medications suppress appetite and accelerate metabolism, resulting in weight loss.

All News

;